As individual investors, most people find it hard to pick stocks because information on public companies, even though it is available, is hard to interpret. Furthermore, looking at stock charts gives only part of the picture, because past performance is not an indication of future value.
Although it is prudent to consult a professional advisor before making investment decisions, let’s pretend we have a ‘crystal ball’ and peek into some companies who have received votes of confidence from financiers. Based on current Venture Capital Investment data from the National Venture Capital Association as well as analysis by Price Waterhouse Coopers (PwC), we may see companies emerging in four main spheres after 2020.
First, in the area of health and wellness there is a huge emergence of new technology, as well as a tremendous need for products and systems which could help an aging population maintain quality of life. Second, in the field of data analysis there is room for development in the face of datafication. Third, in the area of enterprise information, there is a lot of great work being done by an established company who will just grow stronger based on their solid, almost future-proof strategies.
Although nobody is future-proof, some companies manage to create a vision and execute successfully. Finally, since the bring-your-own-device (BYOD) trend is already a reality, a company who creates solutions for mobile enterprise management is of interest and should grow steadily over the next six to ten years.
Health Products And Health Systems
According to a report by Price Waterhouse Coopers (PWC), electronic medical records, e-prescribing and remote monitoring will give healthcare providers and insurance companies who pay for the services access to comprehensive data on outcomes in many countries.
Payers and doctors will be able to assess more easily which medicines are safe, effective and affordable in different patient groups, and they will be able to keep this information in mind when deciding on treatments. Companies who will be successful in this space will be able to harness or add value to the numerous sources of clinical data that will become available.
For example, an oncology database has been established by the US National Comprehensive Cancer Network, which collects socio-demographic, clinical and non-clinical information on cancer patients. The International Serious Adverse Events Consortium aims to develop genetic markers to identify which patients are at risk of serious negative drug-related effects.